Novo Nordisk shares are trading at approximately $40.81 on the today, near the lower end of a 52-week range that stretches from $35.12 to $81.44. The stock has lost roughly 43% of its value over the past year, a decline that reflects a convergence of competitive, pricing and regulatory pressures bearing down on one of the pharmaceutical industry’s most recognised franchises.
Against that backdrop, the Danish drugmaker announced on April 14 a strategic partnership with OpenAI designed to deploy advanced AI across its entire business, from drug discovery to manufacturing, supply chain and commercial operations. Financial terms were not disclosed.
Novo CEO Mike Doustdar said: “There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives. Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever.”
OpenAI CEO Sam Altman said: “AI is reshaping industries and in life sciences, it can help people live better, longer lives. This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.”
Pilot programmes will launch across research and development, manufacturing and commercial operations immediately, with full enterprise-wide integration of OpenAI’s tools targeted by the end of 2026. OpenAI will also help train Novo’s global workforce on AI literacy as part of the deal’s scope. The partnership builds on an existing collaboration with Nvidia to use the Gefion sovereign AI supercomputer for early drug discovery research.
The announcement gave NVO shares a modest lift on the day it was made, though the stock remains under severe structural pressure. Eli Lilly has established dominance in the US obesity drug market, holding more than 60% market share with its tirzepatide-based treatments outpacing semaglutide on prescription volume. Novo’s 2026 guidance calls for adjusted sales growth of negative 5% to negative 13% at constant exchange rates, a sobering outlook for a company that was reporting explosive growth only 18 months ago.
The pricing environment has deteriorated sharply. Novo cut Wegovy and Ozempic prices by up to 48% in India at the start of April in direct response to low-cost generic semaglutide flooding that market. In the United States, a Most-Favoured-Nations pricing agreement with the government and reduced Medicaid coverage have squeezed margins on its flagship products. Eli Lilly also received US approval this month for Foundayo, an oral weight-loss pill, adding another competitive front to a market Novo had previously led.
Not all of the recent news is negative. The FDA approved Wegovy HD, a higher-dose injectable version, on March 19 under a National Priority Voucher with a decision time of just 54 days. Clinical data showed average weight loss of 20.7% over 72 weeks. GoodRx announced on April 15 that Wegovy HD is now available at a self-pay price of $399 per month, an attempt to broaden access beyond insured patients. The FDA also approved Awiqli, the first once-weekly basal insulin for adults with type 2 diabetes, on March 26.
Novo’s oral Wegovy pill, launched on January 5, was generating approximately 50,000 weekly prescriptions by late January. Whether that trajectory is sustained against competition from Eli Lilly’s own oral product will be one of the most closely tracked data points in pharma for the remainder of 2026.
BMO Capital cut its Novo Nordisk price target to $36 from $45 on April 14, citing expectations that Q1 Wegovy pill revenue will lag consensus. Jefferies maintained a Hold rating on April 15. Among 17 analysts tracked by Benzinga, the consensus target stands at $79.28, with the most bullish at $160 and the most bearish at $31. That wide range reflects genuine uncertainty about whether the current earnings contraction is temporary disruption or the beginning of structural margin erosion.
The company’s next catalyst is the regulatory timeline for CagriSema, a next-generation combination therapy combining cagrilintide and semaglutide. Phase 3 data showed 14.2% weight loss in patients with type 2 diabetes, and an FDA decision is expected around the end of 2026 or early 2027. That decision is widely viewed as a binary event for the stock, with a favourable outcome potentially reversing the narrative that Novo has permanently ceded leadership in obesity treatment to Eli Lilly. The OpenAI deal signals that management is not waiting passively for that regulatory moment.
